ConductScience.org, home

Library / Trials

The MInimizing RIsk of CLotting Events Trial

NCT07930429, Not applicable, Not yet recruiting, National Heart, Lung, and Blood Institute (NHLBI)

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleThe MInimizing RIsk of CLotting Events TrialClinicalTrials.gov
NCT numberNCT07930429ClinicalTrials.gov
StatusNot yet recruitingClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment65,000 participants, estimatedClinicalTrials.gov
Lead sponsorNational Heart, Lung, and Blood Institute (NHLBI)ClinicalTrials.gov
ConditionsVenous Thromboembolism (VTE)ClinicalTrials.gov
InterventionsVTE Risk Assessment CDS ToolClinicalTrials.gov
First posted2026-11-12ClinicalTrials.gov
Last updated2026-11-12ClinicalTrials.gov

Registered outcomes 5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryOccurrence of HA-VTEDay 1 (date of patient admission to hospital) until date of discharge from hospital or up to 6 months.Occurence of HA-VTE during hospitalization, identified by diagnostic codes.ClinicalTrials.gov
SecondaryVTE related visits to a VUMC facility90 days post-discharge from hospitalAny VTE related visits to a VUMC facility within 90 days post-discharge, as identified by encounter data in the EHR.ClinicalTrials.gov
OtherNumber of participants who receive pharmacological prophylaxisDay 1 (date of patient admission to hospital) until date of discharge from hospital or up to 6 months.
total number of participants for whom any pharmacological prophylaxis is ordered and administer during hospitalization, defined as the administration of at least 1 dose of the following medications indicated in the MAR (Medication Administration Record) within the electronic health record : APIXABAN BETRIXABAN EDOXABAN RIVAROXABAN DABIGATRAN WARFARIN DALTEPARIN ENOXAPARIN HEPARIN FONDAPARINUX ARGATROBAN BIVALIRUDIN ASPIRIN
ClinicalTrials.gov
OtherNumber of participants who receive non-pharmacological prophylaxisDay 1 (date of patient admission to hospital) until date of discharge from hospital or up to 6 months.
Total number of participants for whom any non-pharmacological intervention is administered during hospitalized (i.e. SCD, ambulation), as indicated by documentation in nursing vascular perfusion flowsheet in the electronic health record: Nursing documentation of ambulation Nursing documentation of SCDs applied to patient
ClinicalTrials.gov
OtherMajor Bleeding complicationsDay 1 (date of patient admission to hospital) until date of discharge from hospital or up to 6 months.
Any major bleeding complications that occur during hospitalization of patient, as defined through the following : * Diagnostic Codes or bleeding (any diagnosis of bleeding at discharge (intracranial, gastrointestinal, hematuria, airway bleeding, anemia due to bleeding/iron deficiency, hemopericardium, and gynecological bleeding) ) * Orders for transfusion (bleeding leading to transfusion of two or more units of whole blood or red cells.) * Lab values indicating a fall in hemoglobin level of 20 g/L-1 (1.24 mmol/L-1) or more
ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 118

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
1754886BACKGROUNDPubMed
8934587BACKGROUNDPubMed
11449339BACKGROUNDPubMed
16217841BACKGROUNDPubMed
16980150BACKGROUNDPubMed
17099194BACKGROUNDPubMed
17569110BACKGROUNDPubMed
18259708BACKGROUNDPubMed
18474755BACKGROUNDPubMed
18573132BACKGROUNDPubMed
19001484BACKGROUNDPubMed
19208371BACKGROUNDPubMed
19664226BACKGROUNDPubMed
20693186BACKGROUNDPubMed
20738765BACKGROUNDPubMed
21083927BACKGROUNDPubMed
21155968BACKGROUNDPubMed
21178018BACKGROUNDPubMed
21757116BACKGROUNDPubMed
21845906BACKGROUNDPubMed

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 4

FieldValueSource
Releasetrials-2026-11-12-0.3.0ClinicalTrials.gov
Release manifest SHA-2564a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.3.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.